Outcome of Board Meeting held on November 12, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of Aspira Pathlab & Diagnostics met on November 12, 2025 and approved two key items. First, the unaudited standalone financial results for Q2 and half-year ended September 30, 2025 showed strong growth: revenue from operations jumped to ₹809.28 lakhs in Q2 FY26 from ₹617.76 lakhs in Q2 FY25 (~31% YoY), and profit after tax nearly doubled to ₹183.54 lakhs from ₹99.03 lakhs. Half-yearly PAT surged to ₹230.49 lakhs vs ₹97.36 lakhs last year. Second, the Board appointed Mrs. Kiran Raghavendra Awasthi (a Chartered Accountant with 28 years of experience) as Additional Independent Director for a 5-year term, subject to shareholder approval. The company also noted the acquisition of Aspira DNA Diagnostics Gujarat LLP's business on a slump sale basis for ₹13 lakhs, effective June 30, 2025, which means no consolidated results are required going forward.
Strong Q2 results with nearly 85% YoY growth in profit and 31% revenue growth signal robust operational momentum. The independent director addition strengthens board governance, while the consolidation of the LLP business simplifies the group structure.